Sponsored Links
| Talactoferrin Benefits Broad Range Of Lung Cancer Patients |
 |
 |
 |
| Medical News - Lung Cancer | |||
|
The investigational immunomodulatory agent talactoferrin boosts survival compared to placebo in multiple prognostically important subsets of patients with non-small cell lung cancer (NSCLC) who have failed first- or second-line therapy, according to phase II data released at the 2011 American Society of Clinical Oncology (ASCO) meeting. P. M... Read more: Lung Cancer News From Medical News Today
|